Testing ASXL1 Gene Variants in Malignant Myeloid Diseases (With Case Studies) | MedGenome

MedGenome Prima Webinar

MedGenome cordially invites you to a webinar on

Testing ASXL1 Gene Variants in Malignant Myeloid Diseases (With Case Studies)

Date & Time:
30th April, 20; 5pm - 6pm

Molecular and genetic tests for leukemias provide the advantage of understanding the clonal drivers at the time of presentation and during the course of disease evolution. It helps in making an informed treatment decision, risk stratification and prognostication in most of the leukemias.

ASXL1 gene is one of the commonly mutated genes in various malignant myeloid diseases. It is estimated that 16.2% of MDS, 34.5% of PMF and 30.3% of AML cases have ASXL1 mutations. Recent studies have shown the important role played by ASXL1 in hematopoiesis, particularly the myeloid lineage. Mutations in ASXL1 are associated with inferior leukemia free survival in MPNs. Understanding the nature of the ASXL1 gene and its function will aid in prognostication of various malignant myeloid diseases.

Dr. G Arun Kumar,

Ph.D (Genomics), Scientific Affairs Manager- MedGenome Labs Ltd

Dr. Rahul Bhargava,

Director & HOD – Haematology, Haemato Oncology and BMT, Fortis Memorial Research Institute, Gurugram

Call in or send us your questions in advance and our experts will address them in this live session.

Can't attend live? You can still REGISTER! We will share the recording of the webinar with all registrants.

Test Menu

Genetic Counselling

Microsites

Collaterals

Contact Us